The occurrence of ventricular fibrillation after occlusion of the circumflex coronary artery in the conscious dog was examined as one preparation for sudden cardiac death arising from coronary artery disease. The incidence of ventricular fibrillation after circumflex occlusion was reduced from 53% to 6% (p < .01) by the infusion of prostacyclin in doses that do not alter cardiac output or peripheral resistance. This effect of prostacyclin led to the evaluation of two structurally different inhibitors of thromboxane synthase in this preparation; RO 22-4679 and U-63557A reduced ventricular fibrillation by 82% and 100%, respectively (p < .05). The inhibition of ventricular fibrillation by U-63557A was abrogated by pretreatment with indomethacin, suggesting that a metabolite of the endoperoxide that accumulated during thromboxane synthase inhibition was responsible for the protection from ventricular fibrillation. Circulation 73, No. 2, 224-226, 1986. 
SUDDEN CARDIAC DEATH is the principal cause of death in industrialized nations, accounting for 50% to 60% of the mortality from coronary artery disease. More than 400,000 persons die annually of sudden cardiac death in the United States. Whereas multiple causes of this phenomenon have been identified, in the majority the essential pathophysiologic features relate to myocardial ischemia with ventricular fibrillation arising in a setting of severe coronary artery atherosclerosis.1 ' 2 Although there are probably multiple mechanisms whereby malignant arrhythmias are generated upon a substrate of severe coronary artery disease, current data indicate that an acute mural thrombosis is causal in most instances. 3 In that study, 74% of the patients with sudden death had acute mural thrombosis that varied in magnitude; 59% of these thromboses caused more than 50% obstruction of the lumen. Most of the thromboses were associated with fissuring of an atherosclerotic plaque.
If plaque fissuring with attendant mural thrombosis is a trigger for many instances of sudden cardiac death, then platelets clearly participate in the process. There is both experimental and clinical evidence that platelet microthrombosis participates in the genesis of lethal arrhythmias.4 ' 224 thelial injury to activate platelets are not reliable for the study of acute arrhythmias and we therefore considered a preparation in which maximal platelet activation could be achieved in a segment of the coronary circulation and one in which ventricular fibrillation frequently occurred. The preparation chosen was balloon occlusion of the circumflex coronary artery in the unanesthetized dog. After this intervention, the occurrence of ventricular fibrillation is largely limited to the first 10 min after occlusion, which is analogous to the rapid occurrence of many instances of human sudden death.
The elfect of prostacyclin on ventricular fibrillation.
Since prostacyclin is the most potent inhibitor of platelet activation, the effect of this drug on occlusionevoked ventricular fibrillation was examined.6 A pneumatic occluder was placed on the left circumflex coronary artery 1 ± 0.4 cm from its origin through the left fourth intercostal space under anesthesia with intravenous sodium pentobarbital (30 mg/kg). At this time catheters also were placed in the left atrium and the aortic arch for pressure monitoring. After 1 week of recovery each animal was sedated with intramuscular morphine sulfate (1 mg/kg) before inflation of the balloon occluder. An initial evaluation of the relationship of the dose of prostacyclin to response revealed that in dogs an infusion of 100 ng/kg/min was effective in suppressing the aggregatory response of platelets ex vivo to 2.5 ,uM ADP, but was without significant hemodynamic action. Accordingly, this dose was selected for administration in a randomized, doubleblind fashion for comparison with infusion of the vehicle. The myocardium at risk was similar in both the control and the prostacyclin-treated animals. Prostacyclin at this infusion rate had a minimal effect on heart rate, blood pressure, systemic vascular resistance, and cardiac output, which was not significant.
Tracings of the electrocardiogram were recorded on magnetic tape. On occlusion, 53% (9/17) of the dogs in the control group fibrillated as compared with 6% (1/17) in the prostacyclin group (p < .01) (table 1, experiment I). This marked reduction in occlusionevoked ventricular fibrillation by prostacyclin suggested that the platelet-vessel wall interaction might be central to the pathophysiology of occlusion-evoked ventricular fibrillation.
The effect of thromboxane synthase inhibitors on occlusion-induced ventricular fibrillation. The ability of prostacyclin to inhibit the ventricular fibrillation attendant to coronary occlusion led to an assessment of a second approach to intervening in this acutely induced interaction of platelets with the coronary vessel wall. In these experiments the animals were pretreated with a thromboxane synthase inhibitor, RO 22-4679, a 1-substituted imidazole.7 Thromboxane synthase inhibition should block the conversion of the prostaglandin endoperoxide PGH2 to thromboxane A2 and consequently cause accumulation of PGH2. The accumulated endoperoxide may then be shunted to other routes of prostaglandin biosynthesis, including conversion to prostacyclin, if the requisite prostacyclin synthase is sufficiently proximate to the platelet source of PGH2. 11 The occurrence of ventricular fibrillation after occlusion of the circumflex coronary artery in unanesthetized dogs was examined with the same approach used in the prostacyclin study. Dogs were randomly assigned, in a blind fashion, to receive either RO 22-4679 (0.3 mg/kg/hr iv) or infusion of vehicle. The group of animals pretreated with RO 22-4679 had a much lower incidence of ventricular fibrillation after occlusion than did the group receiving vehicle (experiment II, table 1).
To ensure that the inhibition of ventricular fibrillation by RO 22-4679 was a consequence of thromboxane synthase inhibition and not some other effect of this molecule, a similar study was conducted with a structurally different thromboxane synthase inhibitor, U-63557A (5-(3' pyridinylmethyl) benzofuran-2-carboxylic acid), infused in a dose of 4 mg/kg. Ventricular fibrillation did not occur in any of the animals receiving U-63557A, whereas there was a 38% incidence in animals receiving vehicle (experiment III, table 1).
Mechanism of action of thromboxane synthase inhibi-
tors. The inhibition of ventricular fibrillation by these two thromboxane synthase inhibitors could be due to blockade of the formation of thromboxane A2 or could have resulted from the shunt of PGH2 to other prostaglandins, including prostacyclin. To examine the role of the endoperoxide shunt in the protective action of the thromboxane synthase inhibitors, an additional group of animals was randomly assigned to receive U-63557A together with 8 mg/kg indomethacin. Concurrent administration of indomethacin completely abrogated the protective effects of U-63557A; ventricular fibrillation occurred in 46% of the animals receiving these two drugs in combination (experiment III, table 1).12
The abrogation of the antifibrillatory effects of a thromboxane synthase inhibitor by concurrent administration of indomethacin supports the hypothesis that the shunt of PGH2 into the biosynthetic pathways of other prostaglandins, including prostacyclin, accounts for the protection from ventricular fibrillation seen in this preparation of acute coronary occlusion. Studies with other cyclooxygenase inhibitors will be required to ensure that this effect of indomethacin can be attributed to its inhibition of cyclooxygenase.
Antiplatelet drugs have been evaluated in preparations of ventricular fibrillation that differ substantially from the one used in these studies. In anesthetized dogs with likely alterations in autonomic function and with much later onset of ventricular fibrillation after occlusion, aspirin protects from occlusion-evoked ventricular fibrillation,13' 14 and thromboxane synthase inhibition protects from reperfusion-induced fibrillation. 15 The bearing of these data on the very early occlusion-induced ventricular fibrillation in the unanesthetized animal is speculative.
The data from the studies on prostacyclin infusion and the two thromboxane synthase inhibitors together imply that prostacyclin is protective against ventricular fibrillation. If augmenting prostacyclin production is protective, the consequence of removing prostacyclin on the propensity for ventricular fibrillation also should be addressed. In this regard, the results of the Aspirin-Myocardial Infarction Study'6 are of note. In this trial, even though the incidence of acute myocardial infarction was reduced by aspirin, the number of sudden deaths was increased (although not statistically significantly so), and the ratio of sudden death to myocardial infarction was 59% greater in the aspirin group than in the placebo group. There are many possible interpretations of these data, including that they are the result of random chance. However, consideration should be given to the possibility that inhibition of prostacyclin synthesis by 1 g/day aspirin increases the probability that an acute intracoronary lesion will result in sudden death before the patient reaches the hospital.
The evidence that most patients experiencing sudden cardiac death have an intramural thrombotic event, usually superimposed on a plaque fissure, taken together with the observation that both prostacyclin and thromboxane synthase inhibition will prevent the ventricular fibrillation evoked by acute coronary occlusion suggest that pharmacologic interventions oriented toward increasing prostacyclin production in the coronary circulation be further evaluated as strategies for the prevention of sudden death. Clearly, the effects of 1 g aspirin daily in the Aspirin-Myocardial Infarction Study must not be considered predictive of the effects of other approaches to antiplatelet therapy that do not inhibit prostacyclin biosynthesis.
